Nanologica AB (SE:NICA)
:NICA
Want to see SE:NICA full AI Analyst Report?
NICA Stock Chart & Stats
kr0.74
kr0.03(1.43%)
At close: 4:00 PM EST
kr0.74
kr0.03(1.43%)
Day’s Range― - ―
52-Week Rangekr0.33 - kr2.25
Previous CloseN/A
Volume105.00
Average Volume (3M)111.94K
Market Cap
kr213.70M
Enterprise Valuekr144.76M
Total Cash (Recent Filing)kr3.55M
Total Debt (Recent Filing)kr21.47M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding328,769,840
10 Day Avg. Volume89,035
30 Day Avg. Volume111,941
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.04
Price to Sales (P/S)3.26
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr83.10M
Bulls Say, Bears Say
Bulls Say
Proprietary Silica Technology PlatformNanologica’s proprietary porous silica and chromatographic media represent a durable product moat in pharmaceutical purification. Platform technology aligns with pharma customers’ long development cycles, enabling recurring consumable sales and service relationships that can sustain revenue once adoption climbs.
Revenue Expanded Versus Prior YearThe increase in absolute revenue versus 2024 indicates improving commercial traction and customer uptake of products/services. If sustained, this revenue base growth supports scale in R&D and manufacturing, improving unit economics and enabling longer-term margin recovery as fixed costs are leveraged.
Manageable Leverage Relative To LiabilitiesReported debt levels are moderate relative to equity, suggesting no immediate solvency strain from leverage alone. This provides the company structural flexibility to pursue operational improvements or raise incremental financing without excessive interest burden if cash generation trends improve.
Bears Say
Negative Gross ProfitA negative gross profit means the company currently loses money on its core product sales after direct costs. This undermines the sustainability of the business model: until gross margins are restored through pricing, yield improvements or cost cuts, scaling sales will deepen losses rather than generate operating leverage.
Large Net LossesPersistent multi-year net losses erode equity and reduce internal funding for growth. Ongoing losses constrain reinvestment in production and commercialization, raise the likelihood of future dilution or restrictive financing, and limit the company’s ability to capitalize on its technology platform.
High Cash Burn And Reduced Equity CushionSizable negative operating and free cash flow combined with a sharply reduced equity base materially increase financing risk. Structural cash burn forces reliance on external capital or dilution absent swift profitability gains, constraining strategic options and making long-term execution riskier.
Nanologica AB News
NICA FAQ
What was Nanologica AB’s price range in the past 12 months?
Nanologica AB lowest stock price was kr0.33 and its highest was kr2.25 in the past 12 months.
What is Nanologica AB’s market cap?
Nanologica AB’s market cap is kr213.70M.
When is Nanologica AB’s upcoming earnings report date?
Nanologica AB’s upcoming earnings report date is Aug 27, 2026 which is in 97 days.
How were Nanologica AB’s earnings last quarter?
Nanologica AB released its earnings results on May 20, 2026. The company reported kr0.719 earnings per share for the quarter, beating the consensus estimate of N/A by kr0.719.
Is Nanologica AB overvalued?
According to Wall Street analysts Nanologica AB’s price is currently Overvalued.
Does Nanologica AB pay dividends?
Nanologica AB does not currently pay dividends.
What is Nanologica AB’s EPS estimate?
Nanologica AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanologica AB have?
Nanologica AB has 328,769,840 shares outstanding.
What happened to Nanologica AB’s price movement after its last earnings report?
Nanologica AB reported an EPS of kr0.719 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 32.383%.
Which hedge fund is a major shareholder of Nanologica AB?
Currently, no hedge funds are holding shares in SE:NICA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanologica AB
Nanologica AB (publ), a nanotechnology company, develops nanoporous silica for applications in the life science industry. The company offers nanoporous silica particles for drug development and chromatography separation. It provides NLAB Silica, a technology platform for drug delivery; NLAB Spiro, an inhalation platform for pulmonary drug delivery; SVEA (U)HPLC analytical columns; and preparative chromatography. Nanologica AB (publ) was founded in 2004 and is based in Södertälje, Sweden.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Biovica International AB Class B
―
NextCell Pharma AB
―
Spago Nanomedical AB
―